After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
Novo Nordisk diversifies with $2.1bn deal to buy CorvidiaNovo Nordisk has taken another step towards expanding beyond its heartlands of diabetes and obesity with a deal Share XNovo Nordisk diversifies with $2.1bn deal to buy Corvidiahttps://pharmaphorum.com/news/novo-nordisk-diversifies-with-2-1bn-deal-to-buy-corvidia/
Coronavirus to disrupt EU pharma drug launches, analysts warnBig European launches of drugs for cancer, HIV, and sickle cell disease could be affected by coronavirus, according Share XCoronavirus to disrupt EU pharma drug launches, analysts warnhttps://pharmaphorum.com/news/coronavirus-to-disrupt-eu-pharma-drug-launches-analysts-warn/
Could GLP-1 drugs treat space headaches? NASA wants to know.Experts from NASA are keeping a close eye on UK research that tests whether drugs commonly used in Share XCould GLP-1 drugs treat space headaches? NASA wants to know.https://pharmaphorum.com/news/nasa-looks-on-as-uk-researchers-test-glp-1-drugs-against-space-headaches/
FDA approves MACE label claim for Lilly’s TrulicityEli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for Share XFDA approves MACE label claim for Lilly’s Trulicityhttps://pharmaphorum.com/news/fda-approves-mace-label-claim-for-lillys-trulicity/
Ozempic acceleration buoys Novo Nordisk, and threatens LillySolid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat Share XOzempic acceleration buoys Novo Nordisk, and threatens Lillyhttps://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/
Novo Nordisk nears EU okay for oral GLP-1 drug Rybelsus after CHMP nodThe EMA’s main advisory committee has backed approval of Novo Nordisk’s oral GLP-1 agonist Rybelsus, a key pipeline Share XNovo Nordisk nears EU okay for oral GLP-1 drug Rybelsus after CHMP nodhttps://pharmaphorum.com/news/novo-nordisk-nears-eu-okay-for-oral-semaglutide-after-chmp-nod/
Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challengeEli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but Share XLilly’s diabetes med Trulicity shrugs off Novo Nordisk challengehttps://pharmaphorum.com/news/lillys-diabetes-med-trulicity-shrugs-off-novo-nordisk-challenge/
Novo’s Ozempic gains MACE risk reduction label in USNovo Nordisk’s Ozempic (semaglutide) weekly GLP-1 injection has gained a new US indication after the FDA agreed a Share XNovo’s Ozempic gains MACE risk reduction label in UShttps://pharmaphorum.com/news/novos-ozempic-gains-mace-risk-reduction-label-in-us/
